

## DAFTAR PUSTAKA

- Abdelnaby, A.A., Azzam, E.A.A. and Afaf Taha, A.T.E. (2022) "Immunohistochemical Expression of Cyclin D1 in Breast Carcinoma," *Egyptian Journal of Hospital Medicine*, 87(1), pp. 2082–2090. Available at: <https://doi.org/10.21608/EJHM.2022.232822>.
- Amir, H. and Murcitra, B.G. (2017) "UJI MICROTETRAZOLIUM (MTT) EKSTRAK METANOL DAUN *Phaleria macrocarpa* (Scheff.) Boerl TERHADAP SEL KANKER PAYUDARA MCF-7," *Alotrop*, 1(1), pp. 27–32. Available at: <https://doi.org/10.33369/atp.v1i1.2711>.
- Arantes, B. *et al.* (2021) "Tagitinin F has anti-inflammatory , anti-nociceptive and anti-matrix metalloproteinase properties : An in silico , in vitro and in vivo study," 164(July 2020). Available at: <https://doi.org/10.1016/j.phrs.2020.105303>.
- Berke, T.P., Slight, S.H. and Hyder, S.M. (2022) "Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer," *Oncotargets and Therapy*, 15, pp. 23–30. Available at: <https://doi.org/10.2147/OTT.S342292>.
- Bhardwaj, P. V. *et al.* (2023) "Advances in the Management of Early-Stage Triple-Negative Breast Cancer," *International Journal of Molecular Sciences*, 24(15). Available at: <https://doi.org/10.3390/ijms241512478>.
- Braicu, C. *et al.* (2019) "A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer," pp. 1–25.
- Cheung, A. *et al.* (2022) "CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models," *Cancers*, 14(14), pp. 1–21. Available at: <https://doi.org/10.3390/cancers14143361>.
- Cömez, B. and Akbuğa, J. (2023) "Effects of Chitosan Nanoparticles with Long Synthetic siRNAs Targeting VEGF in Triple-Negative Breast Cancer Cells," *Brazilian Journal of Pharmaceutical Sciences*, 59. Available at: <https://doi.org/10.1590/s2175-97902023e22304>.
- Dias, K. *et al.* (2017) "Claudin-low breast cancer; clinical & pathological characteristics," *PLoS ONE*, 12(1), pp. 1–17. Available at: <https://doi.org/10.1371/journal.pone.0168669>.
- Fan, Y. *et al.* (2019) "Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway," *Cancer Biology and Therapy*, 20(5), pp. 617–632. Available at: <https://doi.org/10.1080/15384047.2018.1539290>.
- Fayad, F. *et al.* (2013) "Incidence, prévalence, coût," *Encyclopédie Médico-Chirurgicale*, 9, pp. 23–34. Available at: <https://doi.org/10.4137/BCBCR.S25460.TYPE>.
- Gandalovičová, A. *et al.* (2017) "Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges," *Trends in Cancer*, 3(6), pp. 391–406. Available at: <https://doi.org/10.1016/j.trecan.2017.04.008>.

- García, A. and Delgado, G. (2006) “Constituents from *Tithonia diversifolia* . Stereochemical Revision of 2  $\alpha$  -Hydroxytirotonin,” 50, pp. 180–183.
- Goggins, E. *et al.* (2023) “Reprogramming of VEGF-mediated extracellular matrix changes through autocrine signaling,” *Cancer Biology and Therapy*, 24(1), pp. 1–15. Available at: <https://doi.org/10.1080/15384047.2023.2184145>.
- Guo, Y. *et al.* (2020) “ERK/MAPK signalling pathway and tumorigenesis (Review),” *Experimental and Therapeutic Medicine*, pp. 1997–2007. Available at: <https://doi.org/10.3892/etm.2020.8454>.
- Hasnaeni, A.E. (2020) “Sitotoksitas Ekstrak Kayu Beta-Beta (*Lunasia amara*) pada Sel Kanker Payudara T47D,” *Jurnal Sains dan Kesehatan*, 2(3), pp. 193–197.
- Hassan, F. *et al.* (2017) “Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells,” *Saudi Medical Journal*, 38(4), pp. 359–365. Available at: <https://doi.org/10.15537/smj.2017.4.17061>.
- Hu, Y. *et al.* (2021) “Potential prospect of CDK4/6 inhibitors in triple-negative breast cancer,” *Cancer Management and Research*, 13, pp. 5223–5237. Available at: <https://doi.org/10.2147/CMAR.S310649>.
- Hua, Z., White, J. and Zhou, J. (2022) “Cancer stem cells in TNBC,” *Seminars in Cancer Biology*, 82(October 2020), pp. 26–34. Available at: <https://doi.org/10.1016/j.semcancer.2021.06.015>.
- Imamura, T., Hikita, A. and Inoue, Y. (2012) “The roles of TGF- $\beta$  signaling in carcinogenesis and breast cancer metastasis,” *Breast Cancer*, 19(2), pp. 118–124. Available at: <https://doi.org/10.1007/s12282-011-0321-2>.
- Khan, M. *et al.* (2022) “Outcomes of Triple-Negative Breast Cancer Patients in Response to Taxane and Nontaxane-Based Neoadjuvant Chemotherapies,” *Asian Journal of Oncology* [Preprint]. Available at: <https://doi.org/10.1055/s-0042-1750086>.
- Kozłowski, J., Kozłowski, A. and Kocka, J. (2015) “Breast cancer metastasis – insight into selected molecular mechanisms of the phenomenon,” *Postępy higieny i medycyny doświadczalnej (Online)*, 69, pp. 447–451.
- Lei, S. *et al.* (2021) “Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020,” *Cancer Communications*, 41(11), pp. 1183–1194. Available at: <https://doi.org/10.1002/cac2.12207>.
- Lin, C.Y. *et al.* (2022) “Anti-Metastatic Activity of Tagitinin C from *Tithonia diversifolia* in a Xenograft Mouse Model of Hepatocellular Carcinoma,” *Livers*, 2(4), pp. 400–411. Available at: <https://doi.org/10.3390/livers2040030>.
- Lin, H.R. (2012) “Sesquiterpene lactones from *Tithonia diversifolia* act as peroxisome proliferator-activated receptor agonists,” *Bioorganic and Medicinal Chemistry Letters*, 22(8), pp. 2954–2958. Available at: <https://doi.org/10.1016/j.bmcl.2012.02.043>.
- Liu, L. *et al.* (2021) “Proliferation, migration and invasion of triple negative breast cancer cells are suppressed by berbamine via the PI3K/Akt/MDM2/p53 and PI3K/Akt/mTOR signaling pathways,” *Oncology Letters*, 21(1), pp. 1–10.

Available at: <https://doi.org/10.3892/ol.2020.12331>.

- Lukasik, P., Załuski, M. and Gutowska, I. (2021) “Cyclin-dependent kinases (Cdk) and their role in diseases development–review,” *International Journal of Molecular Sciences*, 22(6), pp. 1–33. Available at: <https://doi.org/10.3390/ijms22062935>.
- Lyalkin, S.A. *et al.* (2020) “Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer,” *Experimental Oncology*, 42(2), pp. 140–143. Available at: <https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-2.14579>.
- Mahardika, A.B., Wahyuono, S. and Wahyuningsih, M.S.H. (2016) “Sitotoksitas Senyawa Hasil Isolasi Daun *Tithonia Diversifolia* (Hemsley) A. Gray terhadap Sel T47D, MCF7 dan EVSA-T,” *Journal Majalah Farmaseutik*, 12(2), pp. 401–410.
- Maqbool, M., Bekele, F. and Fekadu, G. (2022) “Treatment Strategies Against Triple-Negative Breast Cancer: An Updated Review,” *Breast Cancer: Targets and Therapy*, 14, pp. 15–24. Available at: <https://doi.org/10.2147/BCTT.S348060>.
- Mardihusodo, H.R., Wahyuningsih, M.S.H. and Astuti, I. (2013) “The effect of active compound isolated from the leaves of kembang bulan [*Tithonia diversifolia* (Hemsley) A. Gray] on cell cycle and angiogenesis of WiDr cell line,” *Journal of the Medical Sciences (Berkala Ilmu Kedokteran)*, 45(03), pp. 101–111. Available at: <https://doi.org/10.19106/jmedscie004503201301>.
- Marvalim, C., Datta, A. and Lee, S.C. (2023) “Theranostics Role of p53 in breast cancer progression : An insight into p53 targeted therapy,” 13(4). Available at: <https://doi.org/10.7150/thno.81847>.
- Migliaccio, G. *et al.* (2023) “Exploring Cell Migration Mechanisms in Cancer: From Wound Healing Assays to Cellular Automata Models,” *Cancers*, 15(21). Available at: <https://doi.org/10.3390/cancers15215284>.
- Obidiro, O., Battogtokh, G. and Akala, E.O. (2023) “Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook,” *Pharmaceutics*, 15(7). Available at: <https://doi.org/10.3390/pharmaceutics15071796>.
- Oliveira, A.M., Ross, J.S. and Fletcher, J.A. (2005) “Tumor Suppressor Genes in Breast Cancer,” *Pathology Patterns Reviews*, 124(suppl\_1), pp. S16–S28. Available at: <https://doi.org/10.1309/5xw3l8lu445qwgqr>.
- Osborne, C., Wilson, P. and Tripathy, D. (2004) “Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications,” *The Oncologist*, 9(4), pp. 361–377. Available at: <https://doi.org/10.1634/theoncologist.9-4-361>.
- Otto, T. and Sicinski, P. (2017) “Cell cycle proteins as promising targets in cancer therapy,” *Nat Rev Cancer*, 17(2), pp. 93–115. Available at: <https://doi.org/10.1038/nrc.2016.138.Cell>.
- Park, M. *et al.* (2022) “Breast Cancer Metastasis: Mechanisms and Therapeutic Implications,” *International Journal of Molecular Sciences*, 23(12). Available at: <https://doi.org/10.3390/ijms23126806>.
- Payan, I. *et al.* (2016) “FAK tyrosine 407 organized with integrin  $\alpha\beta 5$  in Hs578Ts(i)8

- advanced triple-negative breast cancer cells,” *International Journal of Oncology*, 48(5), pp. 2043–2054. Available at: <https://doi.org/10.3892/ijo.2016.3422>.
- Permana, A.W., Permana, Agung Yudistira and Nisa, S. (2019) “Asosiasi Triple Negative Breast Cancer (TNBC) Dengan Mutasi BRCA-1 Dan Etnisitas,” *Medula*, 9(3), pp. 398–404.
- Poorjam, M. and Mohammadi, Z. (2022) “Adenosine Receptor Signaling in Diseases with Focus on Cancer,” *Jorjani Biomedicine Journal*, 10(1), pp. 41–55. Available at: <https://doi.org/10.52547/jorjanibiomedj.10.1.41>.
- Puspitasari, E. *et al.* (2022) “Antiproliferative activity of Ethanolic Extract of Kembang Bulan (*Tithonia diversifolia*) Leaf on HeLa Cervical Cancer Cell Line,” *Indonesian Journal of Cancer Chemoprevention*, 13(1), p. 55. Available at: <https://doi.org/10.14499/indonesianjcanchemoprev13iss1pp55-60>.
- Que, W. *et al.* (2021) “A network pharmacology-based investigation on the bioactive ingredients and molecular mechanisms of *Gelsemium elegans* Benth against colorectal cancer,” *BMC Complementary Medicine and Therapies*, 21(1), pp. 1–18. Available at: <https://doi.org/10.1186/s12906-021-03273-7>.
- Sajjadi, S.E. *et al.* (2015) “Cytotoxic effect of *Cousinia verbascifolia* Bunge against OVCAR-3 and HT-29 cancer cells,” *Journal of HerbMed Pharmacology*, 4(1), pp. 15–19.
- Santi, E., Wahyuningsih, M.S.H. and Budiyanto, A. (2019) “Effect of tagitinin C isolated from *Tithonia diversifolia* (Hemsley) A Gray on migration activity and TGF- $\beta$ 1 levels on keloid fibroblast,” *Journal of the Medical Sciences (Berkala Ilmu Kedokteran)*, 51(03), pp. 188–194. Available at: <https://doi.org/10.19106/jmedsci005103201901>.
- Shah, R., Rosso, K. and David Nathanson, S. (2014) “Pathogenesis, prevention, diagnosis and treatment of breast cancer,” *World Journal of Clinical Oncology*, 5(3), pp. 283–298. Available at: <https://doi.org/10.5306/wjco.v5.i3.283>.
- Song, W. *et al.* (2017) “PARP inhibitor increases chemosensitivity by upregulating MIR-664b-5p in BRCA1-mutated triple-negative breast cancer,” *Scientific Reports*, 7(January). Available at: <https://doi.org/10.1038/srep42319>.
- Stella, S. *et al.* (2023) “Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far,” *OncoTargets and Therapy*, 16(April), pp. 235–247. Available at: <https://doi.org/10.2147/OTT.S379867>.
- Sukumar, J. *et al.* (2021) “Triple-negative breast cancer: promising prognostic biomarkers currently in development,” *Expert Review of Anticancer Therapy*, 21(2), pp. 135–148. Available at: <https://doi.org/10.1080/14737140.2021.1840984>.
- Talhouet, S. De *et al.* (2020) “Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes,” *Scientific Reports*, 10(1), pp. 1–9. Available at: <https://doi.org/10.1038/s41598-020-63759-1>.
- Tsurushima, K. *et al.* (2022) “Dimethyl Fumarate Induces Apoptosis via Inhibition of NF- $\kappa$ B and Enhances the Effect of Paclitaxel and Adriamycin in Human TNBC

- Cells,” *International Journal of Molecular Sciences*, 23(15). Available at: <https://doi.org/10.3390/ijms23158681>.
- Wahyuningsih, M.S., Agung Nugrahaningsih, D.A. and Budiyanto, A. (2019) “Ethanol Extract of *Tithonia Diversifolia* (Hemsley) a. Gray Inhibits Migration Activity and Decrease the Transforming Growth Factor-Beta1, Vegf Expression on Keloid Fibroblasts,” *Asian Journal of Pharmaceutical and Clinical Research*, 12(1), p. 342. Available at: <https://doi.org/10.22159/ajpcr.2019.v12i1.29850>.
- Wahyuningsih, M.S.H. *et al.* (2015) “Isolation and identification of potential cytotoxic compound from kembang bulan [*tithonia diversifolia* (Hemsley) a gray] leaves,” *International Journal of Pharmacy and Pharmaceutical Sciences*, 7(6), pp. 298–301.
- Wang, W. *et al.* (2022) “MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade,” *Nature Communications*, 13(1). Available at: <https://doi.org/10.1038/s41467-021-27921-1>.
- Yip, H.Y.K. and Papa, A. (2021) “Signaling pathways in cancer: Therapeutic targets, combinatorial treatments, and new developments,” *Cells*, 10(3), pp. 1–30. Available at: <https://doi.org/10.3390/cells10030659>.
- Zhao, Z.M. *et al.* (2019) “CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer,” *BMC Cancer*, 19(1), pp. 1–11. Available at: <https://doi.org/10.1186/s12885-019-5290-4>.